Adjunctive treatment with pimavanserin did not result in a statistically significant change from baseline in Positive and Negative Syndrome Scale (PANSS) total score in patients with schizophrenia.
Findings showed a higher incidence of hyperglycemic episodes in patients with diabetes and comorbid schizophrenia than in those without schizophrenia.
People with schizophrenia and cognitive impairment reported significant childhood adversity, especially the lack of parental involvement and family hardships.
Individuals with pediatric-onset bipolar disorder fare better than individuals diagnosed at a later age with the disorder, and bipolar disorder in general is associated with better outcomes than schizophrenia.
Typical antipsychotic use is not associated with an increased risk for strokes compared with atypical antipsychotic use in a non-elderly population and patients without dementia.
A lack of belief in the value of medication and the number of previous hospitalizations also predict hospitalization in first-episode psychosis.
Abnormal neuropsychiatric genetic variants should not be assumed to have an etiologic role if observed in a patient with schizophrenia.
The relative success of NYC START might lead other local governments to fund similar programs to connect individuals with first-episode psychosis to available community supports.
Schizophrenia subsequent to substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome resulting from drug exposure.
Discovering the molecular mechanism of this subtype of schizophrenia could lead to the identification of novel therapeutic targets.